Fig 1.
The peak of chimeric antigen receptor-modified T (CAR-T) cells in blood correlates with tumor burden before commencing lymphodepletion chemotherapy. The peak of CAR-T cells in blood (vector copies/μg DNA) is plotted against (A) the absolute abnormal B cell count in blood; (B) the percentage of abnormal B cells in bone marrow; (C) the tumor cross-sectional area; and (D) the maximum standardized uptake value (SUV) on positron emission tomography imaging. Graphs depict data from all patients treated with cyclophosphamide plus fludarabine and 2 × 106 CAR-T cells/kg, with the exception of one patient who died before the peak of CAR-T cell expansion and is not shown. FlapEF1α, flap elongation factor-1 alpha.